TAK, US8740602052

Takeda stock: Japan filing broadens zasocitinib path

Published on 11/13/2026 at 15:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Takeda stock is in focus after a Japanese filing for zasocitinib covering three psoriasis forms. The drug remains investigational.

Japan filing expands pipeline path

Takeda submitted a Japanese application for zasocitinib, also known as TAK-279, on November 11.
The application covers plaque, pustular and erythrodermic psoriasis after inadequate response to existing treatments.
Further studies are evaluating zasocitinib in psoriatic arthritis and several gastrointestinal and inflammatory diseases.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda Pharmaceutical submitted an application in Japan on November 11, 2026, for approval of zasocitinib, a once-daily oral treatment for three forms of psoriasis. The filing adds a regulatory milestone for the drug, but it is not an approval.

Takeda stock traded at 19.50 euros on Lang & Schwarz at 15:14 CET on Friday, November 13, 2026.

Three proposed psoriasis indications

The application seeks manufacturing and marketing authorization for plaque psoriasis, pustular psoriasis and erythrodermic psoriasis in patients whose existing therapies have not provided an adequate response. Zasocitinib is also known as TAK-279 and is designed as a selective tyrosine kinase 2 inhibitor.

According to IBTimes Japan, the submission is supported by four Phase 3 studies. Two international trials included Japanese participants, while a domestic Phase 3 study evaluated pustular and erythrodermic psoriasis.

Pipeline reach remains broader

The compound remains investigational and has not been approved by any regulatory authority. Takeda is also evaluating it in Phase 3 studies for psoriatic arthritis and in Phase 2 studies for Crohn's disease, ulcerative colitis, nonsegmental vitiligo and hidradenitis suppurativa.

For investors, the Japanese filing broadens the potential regulatory path for a late-stage medicine. The eventual review timeline, approved label and reimbursement conditions remain important factors for any future commercial contribution.